Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1 Университет им. Давида Бен-Гуриона в Негеве. 8410501, Израиль, Беэр-Шева; 2 ГБОУ ВПО «Ставропольский государственный медицинский университет» Минздрава России. 355017, Россия, Ставрополь, ул. Мира, д. 310; 3 ФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава России. 117997, Россия, Москва, ул. Островитянова, д. 1.
Список исп. литературыСкрыть список 1. Демчева НК, Творогова НА. Психиатрическая помощь населению в 2012 году. Аналитический обзор/под ред. профессора ЗИ Кекелидзе и профессора БА Казаковцева-М.: ФГБУ «ГНЦССП им. ВП Сербского» МЗ РФ.-2012.-82 с. 2. Казаковцев БА, Демчева НК, Сидорюк ОВ, Творогова НА, Пронина ЛА. Состояние психиатрических служб и распространённость психических расстройств в Российской Федерации в 2013–2015 годах. Психическое здоровье, 2016:14(7), 3-22. 3. Al Jurdi RK, Dixit LA, Sajatovic M. Role of extended release quetiapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2010;6:29-35. 4. Altamura AC, Moliterno D, Paletta S et al. Effect of quetiapine and norquetiapine on anxiety and depression in major psychoses using a pharmacokinetic approach: a prospective observational study. Clin Drug Investig. 2012;32:213-219. 5. Bergsholm P. Is schizophrenia disappearing? The rise and fall of the diagnosis of functional psychoses: an essay. BMC Psychiatry. 2016;16:387. 6. Björkholm C, Jardemark K, Marcus MM et al. Role of concomitant inhibition of the norepinephrine transporter for the antipsychotic effect of quetiapine. Eur Neuropsychopharmacol. 2013;23:709-720. 7. Blow FC, Zeber JE, McCarthy JF et al. Ethnicity and diagnostic patterns in veterans with psychoses. Social Psychiatry and Psychiatric Epidemiology. 2004;39:841-851. 8. Bortnick B, El-Khalili N, Banov M et al. Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord. 2011;128:83-94. 9. Bowden CL, Grunze H, Mullen J et al A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111-121. 10. Buckley PF, Paulsson B, Brecher M. Treatment of agitation and aggression in bipolar mania: efficacy of quetiapine. J Affect Disord. 2007;100(Suppl 1):S33-S43. 11. Bui K, Earley W, Nyberg S. Pharmacokinetic profile of the extended-release formulation of quetiapine fumarate (quetiapine XR): clinical implications. Curr Med Res Opin. 2013;29:813-825. 12. Clemente AS, Diniz BS, Nicolato R et al. Bipolar disorder prevalence: a systematic review and meta-analysis of the literature. Braz J Psychiatry. 2015;37(2):155-161. 13. Cutler AJ, Datto C, Nordenhem A et al. Extended-release quetiapine as monotherapy for the treatment of adults with acute mania: a randomized, double-blind, 3-week trial. Clin Ther. 2011;33:1643-1658. 14. Ferrari A, Charlson FJ, Norman RE et al. Burden of depressive disorders by country, sex, age, and year: findings from the global burden of disease study 2010. PLoS Med. 2013;10(11): e1001547. 15. Gao K, Wu R, Kemp DE, Chen J et al. Efficacy and safety of quetiapine-XR as monotherapy or adjunctive therapy to a mood stabilizer in acute bipolar depression with generalized anxiety disorder and other comorbidities: a randomized, placebo-controlled trial. J Clin Psychiatry. 2014;75:1062-1068. 16. Ghouse AA, Sanches M, Zunta-Soares G et al. Overdiagnosis of Bipolar Disorder: A Critical Analysis of the Literature. Scientific World Journal. 2013;2013:297087. 17. Grunze H, Vieta E, Goodwin GM et al. WFSBP Task Force On Treatment Guidelines For Bipolar Disorders The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute bipolar depression. World J Biol Psychiatry. 2010;11(2):81-109. 18. Hawkins SB, Bucklin M, Muzyk AJ. Quetiapine for the treatment of delirium. J Hosp Med. 2013;8:215-220. 19. Iordache I, Low NC. The overdiagnosis of bipolar disorder. J Psychiatry Neurosci. 2010; 35(3): E3-E4. 20. Jensen NH, Rodriguiz RM, Caron MG et al. N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A agonist, as a putative mediator of quetiapine’s antidepressant activity. Neuropsychopharmacology. 2008;33(10):2303-2312. 21. Kapur S, Zipursky R, Jones C et al. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry. 2000;57:553-559. 22. Lasalvia A, Penta E, Sartorius N, Henderson S. Is it time to cosign the label schizophrenia to history? An invited commentary. Schizophr Res. 2015;162:276-284. 23. Lee YS, Park IH, Park S-C et al. Johyeonbyung (attunement disorder): renaming mind splitting disorder as a way to reduce stigma of patients with schizophrenia in Korea. Asian J Psychiatry. 2014;8:118-120. 24. Locklear JC, Alemayehu B, Brody RS et al. Treatment patterns, healthcare resource utilization and costs in patients with bipolar disorder, newly treated with extended release or immediate release quetiapine fumarate using US healthcare administrative claims data. Clin Ther. 2013;35:1923-1932. 25. López-Muñoz F, Alamo C. Active metabolites as anti-depressant drugs: the role of norquetiapine in the mechanism of action of quetiapine in the treatment of mood disorders. Front Psychiatry. 2013;4:102. 26. Malhi GS, Tanious M. Optimal frequency of lithium administration in the treatment of bipolar disorder: clinical and dosing considerations. CNS Drugs. 2011;25:289-298. 27. McElroy SL, Weisler RH, Chang W et al. EMBOLDEN II (Trial D1447C00134) Investigators. A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II) J Clin Psychiatry. 2010;71:163-174. 28. Mclntyre RS, Brecher M, Paulsson B et al Quetiapine or haloperidol as monotherapy for bipolar mania – a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573-585. 29. Meltzer HY. Update on typical and atypical antipsychotic drugs. Annu Rev Med. 2013;64:393-406. 30. Mitchell PB. Bipolar disorder: the shift to overdiagnosis. Can J Psychiatry. 2012;57(11):659-65. 31. Mundo E, Cattaneo E, Zanoni S, Altamura AC. The use of atypical antipsychotics beyond psychoses: efficacy of quetiapine in bipolar disorder. Neuropsychiatr Dis Treat. 2006;2:139-148. 32. Muneer A. Pharmacotherapy of bipolar disorder with quetiapine: a recent literature review and an update. Clin Psychopharmacol Neurosci. 2015;13(1):25-35. 33. Pathak S, Findling RL, Earley WR et al. Efficacy and safety of quetiapine in children and adolescents with mania associated with bipolar I disorder: a 3-week, double-blind, placebo-controlled trial. J Clin Psychiatry. 2013;74:e100-e109. 34. Plosker GL. Quetiapine: a pharmacoeconomic review of its use in bipolar disorder. Pharmacoeconomics. 2012;30:611-631. 35. Rasmussen H, Ebdrup BH, Aggernaes B et al. Norquetiapine and depressive symptoms in initially antipsychotic-naive first-episode schizophrenia. J Clin Psychopharmacol. 2013;33:266-269. 36. Riedel M, Müller N, Strassnig M et al. Quetiapine in the treatment of schizophrenia and related disorders. Neuropsychiatr Dis Treat. 2007;3(2):219-35. 37. Ruiz P. Comprehensive textbook of psychiatry. – 2017. 4997 p. ISBN 978-1-4511-0047-1. 38. Sanford M, Keating GM. Quetiapine: a review of its use in the management of bipolar depression. CNS Drugs. 2012;26:435-460. 39. Sanford M. Quetiapine extended release: adjunctive treatment in major depressive disorder. CNS Drugs. 2011;25:803-813. 40. Silverstone PH, Lalies MD, Hudson AL. Quetiapine and Buspirone Both Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic Effects. Front Psychiatry. 2012;3:82. 41. Singh J, Chen G, Canuso CM. Antipsychotics in the treatment of bipolar disorder. Handb Exp Pharmacol. 2012;(212):187-212. 42. Srinivas S, Parvataneni T, Makani R, Patel RS. Efficacy and Safety of Quetiapine for Pediatric Bipolar Depression: A Systematic Review of Randomized Clinical Trials. Cureus. 2020;12(6): e8407. 43. Stahl SM, Lee-Zimmerman C, Cartwright S, Morrissette DA. Serotonergic drugs for depression and beyond. Curr Drug Targets. 2013;14:578-585. 44. Stahl SM. Stahl’s Essential Psychopharmacology: Case studies. Volume 2. Cambridge university press, 2015. 504 p. ISBN 978-1-107-60733-0. 45. Stahl SM. Stahl’s Essential Psychopharmacology: Prescriber’s Guide. Cambridge university press, 2017. 890 p. ISBN 978-1-316-61813-4. 46. Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press. 4rd Ed. 2013. 628 p. ISBN 978-1-107-68646-5. 47. Steel Z, Marnane C, Iranpour С et al. The global prevalence of common mental disorders: a systematic review and meta-analysis 1980–2013. Int J Epidemiol. 2014 Apr;43(2):476-493. 48. Stock EM, Stamey JD, Zeber JE et al. A Bayesian Approach to Modeling Risk of Hospital Admissions Associated With Schizophrenia Accounting for Underdiagnosis of the Disorder in Administrative Records. Comput Psychiatr. 2018;2:1-10. 49. Sümegi A. Quetiapin in bipolar disorders. Neuropsychopharmacol Hung. 2008;10:281-291. 50. Suppes T, Datto C, Minkwitz M et al. Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord. 2010;121:106-115. 51. Suppes T, Vieta E, Gustafsson U, Ekholm B. Maintenance treatment with quetiapine when combined with either lithium or divalproex in bipolar I disorder: analysis of two large randomized, placebo-controlled trials. Depress Anxiety. 2013;30:1089-1098. 52. Suttajit S, Srisurapanont M, Maneeton N, Maneeton B. Quetiapine for acute bipolar depression: a systematic review and meta-analysis. Drug Des Devel Ther. 2014;8:827-38. 53. Suttajit S, Srisurapanont M, Xia J et al. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database Syst Rev. 2013;5:CD007815. 54. Swartz CM, Shorter E. Psychotic depression. New York: Cambridge University Press; 2007. 55. Takahashi H, Ideno T, Okubo S et al. Impact of changing the Japanese term for «schizophrenia» for reasons of stereotypical beliefs of schizophrenia in Japanese youth. Schizophr Res. 2009;112:149-152. 56. Tandon R, Keshavan MS, Nasrallah HA. Schizophrenia, «just the facts»: What we know in 2008, part 1: Overview. Schizophrenia Research. 2008;100(1-3);4-19. 57. Vieta E, Mullen J, Brecher M et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, double- blind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21:923-934. 58. Vieta E, Suppes T, Ekholm B et al. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. J Affect Disord. 2012;142:36-44. 59. Weisler RH, Nolen WA, Neijber A et al. Trial 144 Study Investigators. Continuation of quetiapine versus switching to placebo or lithium for maintenance treatment of bipolar I disorder (Trial 144: a randomized controlled study) J Clin Psychiatry. 2011;72:1452-1464. 60. Woodward TC, Tafesse E, Quon P, Lazarus A. Cost effectiveness of adjunctive quetiapine fumarate extended- release tablets with mood stabilizers in the maintenance treatment of bipolar I disorder. Pharmacoeconomics. 2010;28:751-764. 61. Yatham LN, Goldstein JM, Vieta E et al. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J Clin Psychiatry. 2005;66(Suppl 5):40-48. 62. Yatham LN, Kennedy SH, Parikh S et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2013. Bipolar Disord. 2013;15(1):1-44. 63. Young AH, McElroy SL, Bauer M et al. EMBOLDEN I (Trial 001) Investigators. A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I) J Clin Psychiatry. 2010;71:150-162. 64. Young AH, McElroy SL, Olausson B, Paulsson B Embolden I (D1447C00001); Embolden II (D1447C00134) Investigators. A randomised, placebo-controlled 52-week trial of continued quetiapine treatment in recently depressed patients with bipolar I and bipolar II disorder. World J Biol Psychiatry. 2014;15:96-112. 65. Zimmerman M, Ruggero CJ, Chelminski I et al. Is bipolar disorder overdiag-nosed? J Clin Psychiatry. 2008;69:935-940. 66. Zimmermann P, Brückl T, Nocon A et al. Heterogeneity of DSM-IV major depressive disorder as a consequence of subthreshold bipolarity. Arch Gen Psychiatry. 2009;66:1341-1352.